NCT02810561

Brief Summary

The goal of this study is twofold. First the investigators would like to determine the trajectory of troponin leaks; if it can be shown that the participants who have only minimal elevations of their repeat troponin universally decrease on the 3rd level then future patients may see significantly improved length of stay. Second, given conflicting results in the literature, the investigators would like to determine if elevated troponin levels correlate to later cardiovascular complications. These complications will be defined as Death, Myocardial Infarction, Cardiovascular intervention (such as coronary artery stenting or bypass). As the investigator is a single hospital system in this county it is uniquely positioned to be able to review this retrospectively.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2012

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
4.3 years until next milestone

First Submitted

Initial submission to the registry

April 26, 2016

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 23, 2016

Completed
8 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

August 17, 2022

Status Verified

August 1, 2022

Enrollment Period

4.5 years

First QC Date

April 26, 2016

Last Update Submit

August 15, 2022

Conditions

Supraventricular Tachycardia

Keywords

Troponin

Outcome Measures

Primary Outcomes (1)

  • Troponin-I Level

    Measured in ng/ml

    6 hours after initial EKG

Secondary Outcomes (1)

  • Death/ Need for Cardiac Stent Placement or Coronary Bypass Artery Graft

    6 months

Interventions

No InterventionOTHER

No intervention was completed with this study.

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients presenting to the Emergency Department with Supraventricular Tachycardia and elevated troponin. All sexs, races and ages will be included.

You may qualify if:

  • Supraventricular Tachycardia with troponin elevation

You may not qualify if:

  • Other cardiac arrhythmias or conditions with increased troponin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Tachycardia, Supraventricular

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Matthew Hysell, MD

    Lakeland Health Emergency Department

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 26, 2016

First Posted

June 23, 2016

Study Start

January 1, 2012

Primary Completion

July 1, 2016

Study Completion

July 1, 2016

Last Updated

August 17, 2022

Record last verified: 2022-08